Chronic Myelomonocytic Leukemia (CMML) Overview
Learn About Chronic Myelomonocytic Leukemia (CMML)
View Main Condition: Leukemia
PDGFRB-associated chronic eosinophilic leukemia is a type of cancer of blood-forming cells. It is characterized by an elevated number of white blood cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRB-associated chronic eosinophilic leukemia. Some people with this condition have an increased number of other types of white blood cells, such as neutrophils or mast cells, in addition to eosinophils. People with this condition can have an enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly). Some affected individuals develop skin rashes, likely as a result of an abnormal immune response due to the increased number of eosinophils.
PDGFRB-associated chronic eosinophilic leukemia is caused by genetic rearrangements that join part of the PDGFRB gene with part of another gene. At least 20 genes have been found that fuse with the PDGFRB gene to cause PDGFRB-associated chronic eosinophilic leukemia. The most common genetic abnormality in this condition results from a rearrangement (translocation) of genetic material that brings part of the PDGFRB gene on chromosome 5 together with part of the ETV6 gene on chromosome 12, creating the ETV6-PDGFRB fusion gene.
The exact prevalence of PDGFRB-associated chronic eosinophilic leukemia is unknown. For unknown reasons, males are up to nine times more likely than females to develop PDGFRB-associated chronic eosinophilic leukemia.
PDGFRB-associated chronic eosinophilic leukemia is not inherited and occurs in people with no history of the condition in their families. Chromosomal rearrangements that lead to a PDGFRB fusion gene are somatic variants, which are variants acquired during a person's lifetime and present only in certain cells. The somatic variant occurs initially in a single cell, which continues to grow and divide, producing a group of cells with the same variant (a clonal population).
Mary Bird Perkins Cancer Center
Genevieve Maronge is a Hematologist and an Oncologist in Baton Rouge, Louisiana. Dr. Maronge and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). Her top areas of expertise are Paget Disease of the Breast, Ampullary Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Maronge is currently accepting new patients.
Our Lady Of The Lake Physician Group LLC
Greg Bizette is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Bizette and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Pericarditis, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration. Dr. Bizette is currently accepting new patients.
Mary Bird Perkins Cancer Center
Joseph Shows is a Hematologist Oncology provider in Baton Rouge, Louisiana. Dr. Shows and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Gallbladder Cancer, Gallbladder Adenocarcinoma, Large-Cell Immunoblastic Lymphoma, Sickle Cell Disease, and Bone Marrow Aspiration. Dr. Shows is currently accepting new patients.
Summary: This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs, such as decitabine, work in dif...
Summary: This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called h...
Published Date: December 09, 2022
Published By: National Institutes of Health